Discovery of N-[(3R)-1-Azabicyclo[2.2.2]oct-3-yl]furo[2,3-c]pyridine-5-carboxamide, an Agonist of the α7 Nicotinic Acetylcholine Receptor, for the Potential Treatment of Cognitive Deficits in Schizophrenia: Synthesis and Structure−Activity Relationship
Donn G. Wishka
1
,
Daniel P Walker
1
,
Karen M Yates
1
,
Steven C Reitz
1
,
Shaojuan Jia
1
,
Jason K Myers
1
,
Kirk L. Olson
1
,
E. Jon Jacobsen
1
,
Mark L Wolfe
1
,
Vincent E. Groppi
1
,
Alexander J Hanchar
1
,
Bruce A. Thornburgh
1
,
Luz A Cortes Burgos
1
,
Erik H. F. Wong
1
,
Brian A. Staton
1
,
Thomas J. Raub
1
,
Nicole R. Higdon
1
,
Theron M. Wall
1
,
Raymond S. Hurst
1
,
Rodney R. Walters
1
,
William E Hoffmann
1
,
Mihaly Hajós
1
,
Stanley Franklin
1
,
Galen Carey
1
,
Lisa H. Gold
1
,
Karen K. Cook
1
,
Steven B Sands
1
,
Sabrina X. Zhao
1
,
John R. Soglia
1
,
A. Kalgutkar
1
,
Stephen P. Arneric
1
,
Bruce N. Rogers
1
1
Pfizer Global Research & Development, Eastern Point Road, Groton, Connecticut 06340
|
Publication type: Journal Article
Publication date: 2006-06-10
scimago Q1
wos Q1
SJR: 1.801
CiteScore: 11.5
Impact factor: 6.8
ISSN: 00222623, 15204804
PubMed ID:
16821801
Drug Discovery
Molecular Medicine
Abstract
N-[(3R)-1-Azabicyclo[2.2.2]oct-3-yl]furo[2,3-c]pyridine-5-carboxamide (14, PHA-543,613), a novel agonist of the alpha7 neuronal nicotinic acetylcholine receptor (alpha7 nAChR), has been identified as a potential treatment of cognitive deficits in schizophrenia. Compound 14 is a potent and selective alpha7 nAChR agonist with an excellent in vitro profile. The compound is characterized by rapid brain penetration and high oral bioavailability in rat and demonstrates in vivo efficacy in auditory sensory gating and, in an in vivo model to assess cognitive performance, novel object recognition.
Found
Nothing found, try to update filter.
Found
Nothing found, try to update filter.
Top-30
Journals
|
2
4
6
8
10
12
14
|
|
|
Journal of Medicinal Chemistry
13 publications, 7.56%
|
|
|
British Journal of Pharmacology
9 publications, 5.23%
|
|
|
Journal of Pharmacology and Experimental Therapeutics
5 publications, 2.91%
|
|
|
Psychopharmacology
5 publications, 2.91%
|
|
|
Neuropsychopharmacology
5 publications, 2.91%
|
|
|
Biochemical Pharmacology
5 publications, 2.91%
|
|
|
Bioorganic and Medicinal Chemistry Letters
5 publications, 2.91%
|
|
|
PLoS ONE
4 publications, 2.33%
|
|
|
Neuroscience
4 publications, 2.33%
|
|
|
Brain Research
4 publications, 2.33%
|
|
|
Molecular Pharmacology
3 publications, 1.74%
|
|
|
Pharmacological Research
3 publications, 1.74%
|
|
|
Neuropharmacology
3 publications, 1.74%
|
|
|
European Journal of Pharmacology
3 publications, 1.74%
|
|
|
European Journal of Medicinal Chemistry
3 publications, 1.74%
|
|
|
Synthetic Communications
3 publications, 1.74%
|
|
|
Handbook of Experimental Pharmacology
3 publications, 1.74%
|
|
|
Drug Metabolism and Disposition
2 publications, 1.16%
|
|
|
Assay and Drug Development Technologies
2 publications, 1.16%
|
|
|
Journal of Neuroinflammation
2 publications, 1.16%
|
|
|
Pharmacology Biochemistry and Behavior
2 publications, 1.16%
|
|
|
Neuroscience and Biobehavioral Reviews
2 publications, 1.16%
|
|
|
Bioorganic and Medicinal Chemistry
2 publications, 1.16%
|
|
|
Expert Opinion on Therapeutic Targets
2 publications, 1.16%
|
|
|
International Journal of Neuropsychopharmacology
2 publications, 1.16%
|
|
|
Synlett
2 publications, 1.16%
|
|
|
Molecular Medicine Reports
1 publication, 0.58%
|
|
|
Behavioural Pharmacology
1 publication, 0.58%
|
|
|
Pain
1 publication, 0.58%
|
|
|
2
4
6
8
10
12
14
|
Publishers
|
10
20
30
40
50
60
|
|
|
Elsevier
58 publications, 33.72%
|
|
|
Springer Nature
23 publications, 13.37%
|
|
|
Wiley
22 publications, 12.79%
|
|
|
American Chemical Society (ACS)
19 publications, 11.05%
|
|
|
American Society for Pharmacology and Experimental Therapeutics
10 publications, 5.81%
|
|
|
Taylor & Francis
7 publications, 4.07%
|
|
|
Public Library of Science (PLoS)
4 publications, 2.33%
|
|
|
Ovid Technologies (Wolters Kluwer Health)
3 publications, 1.74%
|
|
|
Frontiers Media S.A.
3 publications, 1.74%
|
|
|
Oxford University Press
3 publications, 1.74%
|
|
|
Mary Ann Liebert
2 publications, 1.16%
|
|
|
American Physiological Society
2 publications, 1.16%
|
|
|
Georg Thieme Verlag KG
2 publications, 1.16%
|
|
|
Spandidos Publications
1 publication, 0.58%
|
|
|
MDPI
1 publication, 0.58%
|
|
|
American Society for Biochemistry and Molecular Biology
1 publication, 0.58%
|
|
|
SAGE
1 publication, 0.58%
|
|
|
SciELO
1 publication, 0.58%
|
|
|
OMICS Publishing Group
1 publication, 0.58%
|
|
|
Scientific Scholar
1 publication, 0.58%
|
|
|
European Molecular Biology Organization
1 publication, 0.58%
|
|
|
Cold Spring Harbor Laboratory
1 publication, 0.58%
|
|
|
Cambridge University Press
1 publication, 0.58%
|
|
|
IMR Press
1 publication, 0.58%
|
|
|
10
20
30
40
50
60
|
- We do not take into account publications without a DOI.
- Statistics recalculated weekly.
Are you a researcher?
Create a profile to get free access to personal recommendations for colleagues and new articles.
Metrics
172
Total citations:
172
Citations from 2024:
6
(3.48%)
Cite this
GOST |
RIS |
BibTex |
MLA
Cite this
GOST
Copy
Wishka D. G. et al. Discovery of N-[(3R)-1-Azabicyclo[2.2.2]oct-3-yl]furo[2,3-c]pyridine-5-carboxamide, an Agonist of the α7 Nicotinic Acetylcholine Receptor, for the Potential Treatment of Cognitive Deficits in Schizophrenia: Synthesis and Structure−Activity Relationship // Journal of Medicinal Chemistry. 2006. Vol. 49. No. 14. pp. 4425-4436.
GOST all authors (up to 50)
Copy
Wishka D. G., Walker D. P., Yates K. M., Reitz S. C., Jia S., Myers J. K., Olson K. L., Jacobsen E. J., Wolfe M. L., Groppi V. E., Hanchar A. J., Thornburgh B. A., Cortes Burgos L. A., Wong E. H. F., Staton B. A., Raub T. J., Higdon N. R., Wall T. M., Hurst R. S., Walters R. R., Hoffmann W. E., Hajós M., Franklin S., Carey G., Gold L. H., Cook K. K., Sands S. B., Zhao S. X., Soglia J. R., Kalgutkar A., Arneric S. P., Rogers B. N. Discovery of N-[(3R)-1-Azabicyclo[2.2.2]oct-3-yl]furo[2,3-c]pyridine-5-carboxamide, an Agonist of the α7 Nicotinic Acetylcholine Receptor, for the Potential Treatment of Cognitive Deficits in Schizophrenia: Synthesis and Structure−Activity Relationship // Journal of Medicinal Chemistry. 2006. Vol. 49. No. 14. pp. 4425-4436.
Cite this
RIS
Copy
TY - JOUR
DO - 10.1021/jm0602413
UR - https://doi.org/10.1021/jm0602413
TI - Discovery of N-[(3R)-1-Azabicyclo[2.2.2]oct-3-yl]furo[2,3-c]pyridine-5-carboxamide, an Agonist of the α7 Nicotinic Acetylcholine Receptor, for the Potential Treatment of Cognitive Deficits in Schizophrenia: Synthesis and Structure−Activity Relationship
T2 - Journal of Medicinal Chemistry
AU - Wishka, Donn G.
AU - Walker, Daniel P
AU - Yates, Karen M
AU - Reitz, Steven C
AU - Jia, Shaojuan
AU - Myers, Jason K
AU - Olson, Kirk L.
AU - Jacobsen, E. Jon
AU - Wolfe, Mark L
AU - Groppi, Vincent E.
AU - Hanchar, Alexander J
AU - Thornburgh, Bruce A.
AU - Cortes Burgos, Luz A
AU - Wong, Erik H. F.
AU - Staton, Brian A.
AU - Raub, Thomas J.
AU - Higdon, Nicole R.
AU - Wall, Theron M.
AU - Hurst, Raymond S.
AU - Walters, Rodney R.
AU - Hoffmann, William E
AU - Hajós, Mihaly
AU - Franklin, Stanley
AU - Carey, Galen
AU - Gold, Lisa H.
AU - Cook, Karen K.
AU - Sands, Steven B
AU - Zhao, Sabrina X.
AU - Soglia, John R.
AU - Kalgutkar, A.
AU - Arneric, Stephen P.
AU - Rogers, Bruce N.
PY - 2006
DA - 2006/06/10
PB - American Chemical Society (ACS)
SP - 4425-4436
IS - 14
VL - 49
PMID - 16821801
SN - 0022-2623
SN - 1520-4804
ER -
Cite this
BibTex (up to 50 authors)
Copy
@article{2006_Wishka,
author = {Donn G. Wishka and Daniel P Walker and Karen M Yates and Steven C Reitz and Shaojuan Jia and Jason K Myers and Kirk L. Olson and E. Jon Jacobsen and Mark L Wolfe and Vincent E. Groppi and Alexander J Hanchar and Bruce A. Thornburgh and Luz A Cortes Burgos and Erik H. F. Wong and Brian A. Staton and Thomas J. Raub and Nicole R. Higdon and Theron M. Wall and Raymond S. Hurst and Rodney R. Walters and William E Hoffmann and Mihaly Hajós and Stanley Franklin and Galen Carey and Lisa H. Gold and Karen K. Cook and Steven B Sands and Sabrina X. Zhao and John R. Soglia and A. Kalgutkar and Stephen P. Arneric and Bruce N. Rogers},
title = {Discovery of N-[(3R)-1-Azabicyclo[2.2.2]oct-3-yl]furo[2,3-c]pyridine-5-carboxamide, an Agonist of the α7 Nicotinic Acetylcholine Receptor, for the Potential Treatment of Cognitive Deficits in Schizophrenia: Synthesis and Structure−Activity Relationship},
journal = {Journal of Medicinal Chemistry},
year = {2006},
volume = {49},
publisher = {American Chemical Society (ACS)},
month = {jun},
url = {https://doi.org/10.1021/jm0602413},
number = {14},
pages = {4425--4436},
doi = {10.1021/jm0602413}
}
Cite this
MLA
Copy
Wishka, Donn G., et al. “Discovery of N-[(3R)-1-Azabicyclo[2.2.2]oct-3-yl]furo[2,3-c]pyridine-5-carboxamide, an Agonist of the α7 Nicotinic Acetylcholine Receptor, for the Potential Treatment of Cognitive Deficits in Schizophrenia: Synthesis and Structure−Activity Relationship.” Journal of Medicinal Chemistry, vol. 49, no. 14, Jun. 2006, pp. 4425-4436. https://doi.org/10.1021/jm0602413.